^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Rectal Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy

    Excerpt:
    ...An ARMS-PCR proven KRAS, NRAS mutation, excluding BRAF mutation or microsatellite instablility-High; 3....
    Trial ID:
    NCT05111860
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Comput Math Methods Med
    Title:

    Neoadjuvant Chemotherapy plus Bevacizumab Combined with Total Mesorectal Excision in Treating Locally Advanced Rectal Cancer Patients with BRAF Mutation: Clinical Benefit and Safety

    Published date:
    12/09/2021
    Excerpt:
    To investigate clinical benefit and safety of neoadjuvant chemotherapy (NAC) plus bevacizumab combined with total mesorectal excision (TME) in treating patients with BRAF-mutated locally advanced rectal cancer (LARC)….Patients in the control group received a standard treatment regimen of TME combined with NAC (n = 45), and patients in the observation group received NAC plus bevacizumab combined with TME (n = 55)....In terms of long-term clinical benefit, the RFS of patients in the observation group was evidently longer (p = 0.037) than that in the control group.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1155/2021/4227650